AUROPHARMA — Aurobindo Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Aurobindo Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	247,746	234,555	248,554	290,019	317,237
Cost of Revenue
Gross Profit	139,693	124,020	125,295	153,417	174,076
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	175,409	203,992	223,417	248,714	267,677
Operating Profit	72,337	30,563	25,136	41,305	49,561
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	73,436	33,727	26,125	43,800	50,663
Provision for Income Taxes
Net Income After Taxes	53,338	26,471	19,277	31,690	34,836
Minority Interest
Net Income Before Extraordinary Items
Net Income	53,348	26,482	19,275	31,730	34,859
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	53,348	26,482	19,275	31,730	34,859
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	57.9	47.4	33	57	60.1
Dividends per Share